

Pure-AMC

HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells

Nijmeijer, Bernadien M; Sarrami-Forooshani, Ramin; Steba, Gaby S; Schreurs, Renée Rce; Koekkoek, Sylvie M; Molenkamp, Richard; Schinkel, Janke; Reiss, Peter; Siegenbeek van Heukelom, Matthijs L; van der Valk, Marc; Ribeiro, Carla Ms; Geijtenbeek, Teunis Bh

Published in:

Journal of the International AIDS Society

DOI:

[10.1002/jia2.25268](https://doi.org/10.1002/jia2.25268)

Published: 01/03/2019

Document Version

Publisher's PDF, also known as Version of record

Citation for pulished version (APA):

Nijmeijer, B. M., Sarrami-Forooshani, R., Steba, G. S., Schreurs, R. R., Koekkoek, S. M., Molenkamp, R., Schinkel, J., Reiss, P., Siegenbeek van Heukelom, M. L., van der Valk, M., Ribeiro, C. M., & Geijtenbeek, T. B. (2019). HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells. *Journal of the International AIDS Society*, 22(3), e25268. <https://doi.org/10.1002/jia2.25268>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells

Bernadine M Nijmeijer¹, Ramin Sarrami-Forooshani¹, Gaby S Steba², Renée RCE Schreurs¹, Sylvie M Koekkoek², Richard Molenkamp², Janke Schinkel², Peter Reiss^{3,4}, Matthijs L Siegenbeek van Heukelom^{4,5}, Marc van der Valk⁴, Carla MS Ribeiro¹  and Teunis BH Geijtenbeek^{1§} 

§Corresponding author: Teunis BH Geijtenbeek, Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Tel: +31 (0)20 56 66063. (t.b.geijtenbeek@amc.uva.nl)

Abstract

Introduction: The significant rise in incidence of Hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) living with HIV-1 suggests that HCV under specific circumstances is transmitted via sexual contact. During sexual transmission HCV has to cross the epithelial barrier to either directly enter the blood stream or indirectly via mucosal immune cells. However, the mechanisms of sexual transmission of HCV remain unclear. We investigated the role of Langerhans cells (LCs) in HCV susceptibility during sexual contact as LCs are among the first cells in mucosal tissues to encounter invading viruses.

Methods: We investigated the phenotype of primary LCs in anal biopsies from MSM living with HIV-1. To investigate the role of primary LCs in HCV infection and transmission, we have used both isolated primary skin LCs and the *ex vivo* tissue transmission model.

Results: Our data identified an important role for mucosal LCs in facilitating HCV transmission after HIV-1 exposure or immune activation. LCs were detected within mucosal anal tissues obtained from HIV-1 positive MSM biopsies. In order to perform functional studies, we used primary LCs from skin, which have a similar phenotype as mucosal LCs. Immature LCs were neither infected nor transmitted HCV to hepatocytes. Notably, exposure to HIV-1 significantly increased HCV transmission by LCs in the *ex vivo* transmission model. HIV-1 replication was crucial for the increased HCV transmission as HIV-1 inhibitors significantly reduced HIV-1-induced HCV transmission. Moreover, tissue immune activation of LCs also increased HCV transmission to target cells.

Conclusions: Thus, our data strongly indicate that HIV-1 or immune activation in MSM leads to capture of HCV by mucosal LCs, which might facilitate transmission to other cells or allow entry of HCV into the blood. This novel transmission mechanism by LCs also implicates that the activation state of LCs is an important cellular determinant for HCV susceptibility after sexual contact.

Keywords: HIV-1; Langerhans Cells; Hepatitis C virus; Immune activation; Viral transmission; Men-who-have-Sex-with-Men

Additional Supporting Information may be found online in the Supporting information tab for this article.

Received 3 July 2018; Accepted 5 March 2019

Copyright © 2019 The Authors. *Journal of the International AIDS Society* published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

Globally, 115 million people are infected with Hepatitis C virus (HCV) whereas 37 million people are infected with HIV-1, and approximately two million infected with both HIV-1 and HCV [1]. Hepatitis C virus infection has been recognized as an emerging infection in man-who-have-sex-with-man (MSM) [2]. Studies indicated that HIV-1 status is an important factor for sexually acquired HCV [3–6] but recent studies suggest that sexual transmission also occurs among HIV-uninfected MSM [7,8]. Thus, HCV is sexually transmitted but the

mechanisms remain unclear. Individuals living with HIV-1 are less likely to spontaneously clear HCV infection during acute infection, have higher HCV viral loads, and experience more rapid liver fibrosis progression than those without HIV-1 infection

[9–11]. Moreover, mucosal tissue damage as well as sexual practices leading to rectal bleeding are factors that can enhance HCV susceptibility after sexual contact [12]. Hepatitis C virus infection in individuals living with HIV-1 has a major impact as in the developed world, end-stage liver disease is a leading cause of death among HIV-1 positive individuals [13].

Although treatment with directly acting antivirals (DAA) against HCV is very effective in clearing HCV [14], MSM living with HIV-1 remain at high risk of reinfection [4,15,16]. These recent studies suggest that HCV is sexually transmitted within MSM [17], whereas sexual transmission of HCV within heterosexual HIV-1 infected or uninfected individuals is rare [18]. Apart from intravenous drug use, factors for acquiring HCV are receptive unprotected anal intercourse and other sexual risk behaviour [19,20]. It has also been shown that HCV is shed into the rectum in HIV-1 positive men with HCV infection [21]. These studies strongly suggest that the rectal mucosa is the primary entry site for HCV entry in MSM after sexual contact, and that unknown mechanisms allow changes within the mucosa that increase susceptibility to HCV. HIV-1 infection might directly affect the activation of mucosal immune cells, or cause defective mucosal barrier [22], whereas in uninfected MSM other sexually transmitted infections (STIs) might change the mucosal barrier allowing HCV entry.

Interestingly, how HCV after entry into mucosa reaches the blood and liver remains unclear. Dendritic cell (DC) subsets play a role in sexual transmission of viruses such as HIV-1 across mucosal tissues [23]. Several studies have shown that submucosal DCs are able to capture HCV and transmit the virus to neighbouring human liver cells [24,25]. Mucosal Langerhans cells (LCs) have been identified in human sigmoid colon and rectal mucosal tissues [26], therefore LCs could be among the first cells that encounter HCV upon sexual transmission in MSM. Little is known about the function of mucosal LCs in HCV susceptibility. Here we show an important role for mucosal LCs in HCV transmission. We identified mucosal LCs in anal biopsies from MSM living with HIV-1. As the cell numbers are very low we used primary LCs from skin to investigate their function in HCV transmission. Our data strongly suggest that under normal conditions LCs are refractory to HCV but upon activation or HIV-1 infection, LCs capture HCV. This might allow either transmission to other cells such as lymphocytes that subsequently migrate into the blood or allow the virus to survive long enough to enter the blood. Thus efficient capture and retention of HCV in mucosal tissues by LCs might increase HCV susceptibility in MSM.

2 | METHODS

2.1 | Antibodies and reagents

The following reagents were used: tripalmitoylated-lipopeptide Pam3CSK4 (5 µg/mL) (Invivogen, San Diego, CA, USA), recombinant human TNF (1 µg/mL) (R&D Systems, Minneapolis, MN, USA). The following antibodies were used (all anti-human): CD3-AF700, CD3-PerCP (BD Biosciences, San Jose, CA, USA), CD19-FITC, CD20-FITC, CD56-FITC, (Thermo Fisher Scientific, Waltham, MA, USA), CD45-V500, (BD Horizon, USA), CD1a-APC (BD Biosciences, San Jose, CA, USA), CD207-PE (Beckman Coulter, Indianapolis, IN, USA), DC-SIGN-FITC (R&D Systems) and anti-HIV-1 p24, KC57-RD1-PE, (Beckman Coulter). The following reagents were obtained through the NIH AIDS Reagent Program, NIAID: Zidovudine (10 µmol/L), Raltegravir (100 nmol/L) and Indinavir (1 µmol/L).

The following plasmids were provided by Dr. Takaji Wakita at Tokyo Metropolitan Institute of Neuroscience: Genotype

2a HCV genomic RNA clone pJFH1 (APP1025) [27]. pJFH1-AM120-Rluc was provided by Dr. Curt Hagedorn at University of Utah, Salt Lake City, USA. pNL4.3.Luc_RΔenv provided by Dr. N.R. Landau [28], pHCV_H77_E1_E2 (AF009606) Dr. Joe Grove (Addgene) [29].

2.2 | Cell lines

Huh7.0 (human hepatocellular carcinoma) cell line was obtained from the Health Science Research Resources Bank (JCRB0403; Osaka, Japan). Cells were maintained in Dulbecco modified Eagle medium (Gibco Life Technologies, Gaithersburg, MD) containing 10% fetal calf serum (FCS) and penicillin/streptomycin. Huh7.5 cells were provided by Dr. Charles M. Rice [30]. Medium was supplemented with 1 mmol/L HEPES buffer (Gibco Life Technologies). MUTZ-LCs were differentiated from CD34⁺ human AML cell line MUTZ3 progenitors in the presence of GM-CSF (100 ng/mL; Thermo Fisher Scientific), TGF-β (10 ng/mL; R&D Systems) and TNF-α (2.5 ng/mL, R&D Systems) and cultured as described before [31].

2.3 | HIV-1 and HCV virus stocks

The following virus stocks were obtained through the NIH AIDS Reagent Program, division of AIDS, NIAID: HIV-1 JR-CSF Virus from Dr. Irvin Chen [32,33], HIV-1 SF162 Virus from Dr. Jay Levy [34]. HIV-1 virus stocks were propagated on PHA-stimulated human PBMCs. Produced HIV-1 viruses were quantified by p24 ELISA (Perkin Elmer Life Sciences, Boston, MA, USA) and titrated using the indicator cells TZM-bl (John C. Kappes, Xiaoyun Wu, Birmingham, Alabama, USA and Tranzyme Inc., the NIH AIDS Reagent Program, division of AIDS, NIAID) [35]. For single-round infection assay, human embryonic kidney 293T/17 cells (ATCC, CRL-11268) were co-transfected with pNL4.3.Luc_RΔenv, containing firefly luciferase gene at the *nef* position (1.35 µg) and pHCV_H77_E1_E2(AF009606) (0.6 µg). Transfection was performed in 293T/17 cells using genejuice (Novagen, Merck millipore, Burlington, MA, USA) transfection kit according to the manufacturer's protocol. At day 2, pseudotyped HCV was harvested and filtered over 0.45 µm nitrocellulose membrane (SartoriusStedim, Gottingen, Germany). JFH1-AM120-Rluc In vitro transcribed RNA was generated according to the manufacturer's instructions (Ambion MEGAscript-kit; Thermo Fisher Scientific, Waltham, MA, USA) and electroporated into Huh7.5 cells as previously described [36]. Virus particles were harvested on day 8 and, TCID50s were determined. The TCID50 of HCV ranged from 2×10^3 to 4×10^3 .

2.4 | HIV-1 anal biopsies analysis

Anal biopsies from HIV-1 positive MSM under cART [37] were taken from the anal transformation zone following the "2016 IANS International guidelines for practice standard" [38]. Samples were minced and incubated for one hour at 37°C with IMDM (Thermo Fischer Scientific) containing 1 mg/mL Collagenase D (0.15 U/mg; Roche, Switzerland) 1% FCS and 1000 U/mL DNase type I (Roche Applied Sciences, Mannheim, Germany), pushed through a 70 µm single-cell strainer (Falcon, VWR, United Kingdom). Single-cell suspension was washed,

stained with monoclonal antibodies (all anti-human), 30 minutes at 4°C. Cells were washed with PBS, resuspended in 1× stabilizing fixative (BD Biosciences) [39]. Flowcytometric analyses were performed on LSR Fortessa (BD) 24 hours after fixation. Data were analysed using FlowJo vX.0.7 software (TreeStar Inc, Ashland, OR, USA).

2.5 | Ex vivo model and primary LC isolation

Epidermal sheets were prepared as described previously [40,41]. Briefly, skin-grafts were obtained using a dermatome (Zimmer Biomet, Indianapolis, IN, USA). After incubation with Dispase II (1 U/mL; Sigma Aldrich, Saint Louis, Missouri, USA), epidermal sheets were separated from dermis, washed, cut in 1 cm² and cultured in Iscoves Modified Dulbecco's Medium (IMDM; Thermo Fischer Scientific) supplemented with 10% FCS, gentamycin (20 µg/mL; Centrafarm, Etten-Leur, The Netherlands), penicillin/streptomycin (10 U/mL and 10 µg/mL respectively; Invitrogen). LC-enriched epidermal single-cell suspensions were generated as described before [40,41]. Briefly, epidermal sheets were incubating in PBS containing DNase I (20 units/mL; Roche Applied Science, Mannheim, Germany) and trypsin 0.05% (Beckton Dickinson, USA). Single-cell suspension was layered on Ficoll gradient (Axis-shield) and immature LCs were purified using CD1a microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). LCs were routinely 85% to 98% pure and expressed high levels of Langerin and CD1a [23]. Mature LCs were generated as described before [40]. Briefly, epidermal sheets were cultured in IMDM (Thermo Fischer Scientific) supplemented with 10% FCS, gentamycin (20 µg/mL; Centrafarm, Etten-Leur, The Netherlands), penicillin/streptomycin (10 U/mL and 10 µg/mL respectively; Thermo Fisher Scientific) for three days and mature LCs were harvested.

2.6 | Ex vivo transmission and co-culture

Epidermal sheets were incubated with Raltegravir (100 Nmole/L) or Indinavir (1 µmole/L), and after two hours exposed to JRCSF (100 µL/sheet, TCID50 of 38 × 10³, determined in TZM-BL cells) for 24 hours and subsequently to replicative HCV or pseudotyped HCV for another 24 hours. After 48 hours cells were harvested, extensively washed to remove unbound virus and co-cultured with Huh7.0 or Huh7.5 for five days at 37°C. Luciferase activity (relative light units (R.L.U.)) was measured using the Luciferase assay system (Promega, Madison, WI, USA) according to manufacturer's instructions.

2.7 | Strand-specific quantitative real-time PCR

Specific amplification of HCV minus strand RNA was performed as previously described [42], modified for Taqman realtime PCR. cDNA of the HCV minus strand was generated by reverse transcription using thermoscript (Thermo Fisher Scientific) and primer tag-RC1 (5'-ggcgcgtcatggcgcaataaGTCTA GCCATGGCGT TAGTA-3') according to manufacturer instructions. Subsequently the tagged minus strand cDNA was amplified and detected by realtime Taqman PCR using a tag-specific primer, RC21 (5'-CTCCCGGGGCACTCGCAAGC-3'), and FAM-labelled Taqman probe HCV-5UTR (5'-CTCCCGG GAGAGCCATAGTGGTCTGCG-3') using LC480 Probesmas-

ter (Roche Applied Science) according to manufacturer instructions. PCR conditions were as follows: two minutes at 50°C and ten minutes at 95°C, followed by 45 cycles each consisting of fifteen seconds at 95°C and one minutes at 60°C. Ct values above 36 were considered background, based on negative control experiments.

2.8 | HCV binding and uptake assay

Mature LCs were exposed to pseudotyped HCV for 5h at 4°C or 37°C, harvested, trypsinized, washed, lysed and measure for p24 ELISA (Perkin Elmer Life Sciences) according to manufacturer instructions.

2.9 | Cell sorting

Mature LCs were sorted using CD1a-APC and CD3-PerCP and analysed on a FACS Aria (BD). CD3 negative and CD1a positive mature LCs were exposed to pseudotyped HCV, after 24 hours cells were harvested, extensively washed and co-cultured with Huh7.5 for five days at 37°C.

2.10 | Statistics

Two-tailed Student's *t*-test for paired observations (differences between different donors) or unpaired observation (differences within the same donor). Statistical analyses were performed using GraphPad Prism 7 software and significance was set at **p*<0.05, ***p*< 0.01****p*< 0.001*****p*< 0.0001.

2.11 | Study approval

HIV-1 anal biopsy samples for this study were collected after written informed consent was given by the participant. Sample collection was approved by the local ethical committee under project/reference number: 05/031. Human skin tissue was obtained from healthy donors undergoing corrective abdominal surgery in accordance with our institutional guidelines. This study was approved by the Medical Ethics Review Committee of the Academic Medical Center (W15_089 # 15.0103). Biopsy samples were collected from November 2016 until May 2017. The whole of this study was conducted from January 2015 until January 2018.

3 | RESULTS

3.1 | Langerhans cells are present in anal mucosal biopsies from HIV-1 infected MSM

Here, we investigated the presence of LCs in anal mucosa. Single-cell suspensions of biopsies from MSM living with HIV-1 were analysed by flow cytometry (Figure S1A,B) [39]. Notably, a LC population based on the LC-markers CD1a and Langerin (CD207) was detected in multiple donors. The absolute number of LCs ranged from 80 to 120 in a 5 by 5 mm biopsy (Figure 1A). Interestingly, the phenotype as well as total number of LCs from colonic mucosa was similar to those observed in epidermal sheets (Figure 1B). Moreover, mucosal LCs did not express DC-SIGN, similar as skin-derived LCs (Figure S2A, B,C), further indicating that these mucosal cells are LCs. These data suggest that anal mucosa contains similar amount of LCs




Figure 1. Langerhans cells are present in anal mucosal biopsies from HIV-1 infected MSM.

(A) Single cell suspensions of anal biopsies from HIV-1 infected individuals were stained with antibodies against CD45, CD19, CD20, CD56, CD3, CD1a and CD207 and analysed by flow cytometry. The percentage of cells present is depicted in the upper-right corner of the dot plots. Four representative donors out of six donors is depicted. **(B)** Single cell suspensions of epidermal sheets were stained with antibodies against CD1a and CD207 and analysed by flow cytometry. One representative donor is depicted. D1, Donor 1; D2, Donor 2; D3, Donor 3; D4, Donor 4.

as observed in epidermis, which strongly indicates that anal mucosal LCs might have an important function in defence against pathogens and might be an important target for HCV upon infection.

3.2 | Immature, mature and activated Langerhans cells do not become infected by HCV

We investigated whether HCV infects primary immature LCs using a replicative HCV genotype 2a strain containing a luciferase reporter gene (JFH1-AM120-Rluc), that expresses luciferase upon replication [36]. Due to the low amounts of LCs from biopsies, LCs were isolated from human skin epidermis [40]. Both immature and mature LCs were exposed to

replicative HCV for six days or left uninfected. Notably, neither immature nor mature LCs were infected by HCV (Figure 2A,B). Moreover, activation of mature LCs by TLR ligands did not induce infection of LCs by HCV (Figure 2A). Furthermore, no replication intermediates were detected in both immature and mature LCs by negative strand PCR, whereas the hepatocyte cell-line Huh7.5 was efficiently infected (Figure 2B). These data strongly indicate that neither immature, mature nor activated LCs are infected by HCV. Several studies showed that immature submucosal DCs are able to transmit HCV via DC-SIGN [24,25]. Therefore we investigated whether immature LCs could also transmit HCV. Both Immature LCs and DCs were incubated with infectious HCV (JFH1-AM120-Rluc) for 24 hours, and after extensive washing




Figure 2. Immature, mature and activated Langerhans cells do not become infected by HCV.

(A) Immature and mature LCs were isolated and stimulated with Pam3CSK4 (TLR2) (5 μ g/mL) and TNF (1 μ g/mL), after two hours, cells were infected with infectious HCV (JFH1) for six days and analysed for luciferase reporter activity. Error bars are the mean \pm SD of $n=2$ (immature LCs) and $n=4$ (mature LCs) donors measured in duplo and $n=3$ (Huh7.5 cell line) in quadruplo. *** $p < 0.001$, by two-tailed, unpaired Student's t -test. **(B)** Immature and mature LCs were isolated and infected with infectious HCV (JFH1) for six days and analysed for negative strand RNA by real-time PCR normalized to beta-globuline. Error bars are the mean \pm SD of $n=3$ (immature LCs), $n=4$ (mature LCs) donors measure in duplo, and $n=3$ (Huh7.5 cell line) in triplo and quadruplo. *** $p < 0.001$, by two-tailed, unpaired Student's t -test. **(C)** Immature LCs and moDCs were isolated and infected with infectious HCV (JFH1) for 24 hours, extensively washed, co-cultured with huh7.5 cells and analysed for luciferase reporter activity. Error bars are the mean \pm SD of $n=3$ (immature LCs) donors measured in duplo and $n=3$ (moDCs) measured in triplo. * $p < 0.05$, ns, not significant, by two-tailed, unpaired Student's t -test. HCV, Hepatitis C virus; iLC, immature langerhans cell; mLC, mature langerhans cell; moDC, monocyte derived dendritic cell; UI, uninfected.

co-cultured with Huh7.5 cells. In contrast to DCs, co-culture of HCV-treated immature LCs with hepatocyte cell-line did not result in HCV infection of the hepatocytes (Figure 2C), strongly suggesting that immature LCs in contrast to immature DCs are not able to retain HCV for transmission to target cells.

3.3 | HIV-1 replication enhances HCV transmission by LCs ex vivo

As HCV transmission occurs in MSM living with HIV-1, we investigated the effect of HIV-1 on HCV transmission in the *ex vivo* tissue transmission model [23]. *Ex vivo* tissues were exposed to HIV-1 for 24 hours and subsequently exposed to HCV (JFH1-AM120-Rluc) for another 24 hours. LCs migrated from these tissues had a mature phenotype [23]. After 48 hours emigrated LCs were harvested, extensively washed and co-cultured with Huh7.5 cells, and infection was measured by luciferase activity. Hepatitis C virus exposure to tissue *ex vivo* resulted in low levels of HCV transmission by LCs to hepatocytes. Strikingly, HIV-1 pre-exposure to tissues *ex vivo* significantly increased HCV transmission of LCs to hepatocytes (Figure 3A). These data strongly suggest that HIV-1 exposure allows LCs to capture infectious HCV and retain the virus for transmission to target cells. To further investigate whether HIV-1 infection is necessary for LCs to retain and transmit infectious virus, we treated *ex vivo* tissue with HIV-1 integrase inhibitor Raltegravir and protease inhibitor Indinavir prior to HIV-1 exposure. Notably, treatment of the tissue with the different anti-retroviral inhibitors abrogated HCV transmission by HIV-1-exposed LCs to target cells (Figure 3B). HIV-1 infection of LCs was blocked by the different HIV-1 inhibitors (Figure S3). These data strongly suggest that active HIV-1 replication is required for the observed induction of HCV transmission. To investigate whether HIV-1 affects the number of emigrated cells we quantified the migration of LCs

from *ex vivo* epidermal sheets by flow cytometry. *Ex vivo* tissues were exposed to either medium, HIV-1 or Indinavir or Raltegravir and HIV-1 for 48 hours, harvested and counted by flow cytometry. There was no significant difference in absolute cell counts between unexposed and HIV-1 exposed samples in presence or absence of inhibitors (Figure 3C). Therefore, these data suggest that HIV-1 replication in the *ex vivo* tissue model affects the function of LCs facilitating HCV capture and transmission by LCs.

3.4 | Mature and HIV-1-infected LCs retain infectious HCV for transmission

As we did not observe any infection of mature LCs by HCV, we investigated whether HIV-1 infected LCs transmit HCV independent of replication using HCV pseudotyped single-round virus, LCs exposure to HCV pseudotyped viruses *ex vivo* resulted in low levels of HCV transmission but, HIV-1 exposure significantly increased transmission of HCV pseudotyped viruses by LCs (Figure 4A). These data strongly indicate that HIV-1 infection increases the ability of LCs to retain infectious HCV viruses, resulting in HCV transmission independent of infection.

Next, we investigated whether the maturation of LCs affects HCV transmission. Mature LCs were isolated from a three-day culture of epidermal sheets [40]. These emigrated LCs had a mature phenotype as shown by the higher expression levels of co-stimulatory molecules CD80 and CD86, and decreased Langerin expression, compared to immature LCs [41]. Mature LCs were exposed to HCV pseudotyped virions for 24 hours, washed and co-cultured with Huh7.5 cells for 5 days. Strikingly, mature in contrast to immature LCs transmitted HCV to target cells (Figure 4B). Moreover, sorted CD3-negative, CD1a-positive LCs as well as CD34-derived MUTZ-LCs transmitted HCV to target cells (Figure S4A,B). These data exclude that LCs and not contaminating T cells




Figure 3. HIV-1 replication enhances HCV transmission by LCs ex vivo.

(A–B) Epidermal sheets were floated on medium in a 24-well plate and exposed to either HIV-1 (JRCSF) or HIV-1 (SF162) for 24 hours and subsequently exposed to infectious HCV (JFH1-AM120-Rluc) for another 24 hours. Emigrated cells were harvested, extensively washed, co-cultured with huh7.5 cells and analysed for luciferase reporter activity. (A) Each dot represents 1 donor. Horizontal bars are the means of $n=10$ donors measured in triplo or quadruplo. *** $p < 0.001$ by two-tailed, paired Student's *t*-test. (B) Epidermal sheets were pre-exposed to HIV-1 replication inhibitors Raltegravir or Indinavir for two hours. Each dot represents 1 donor. Horizontal bars are the means of $n=7$ donors measured in quadruplo. * $p < 0.05$, ** $p < 0.01$, by two-tailed, paired Student's *t*-test. (C) Epidermal sheets were pre-exposed to HIV-1 replication inhibitors Raltegravir or Indinavir for two hours, exposed to either medium only or HIV-1 (JRCSF) for 48 hours. Emigrated LCs were harvested, stained with an antibody against CD1a and absolute cell count beads and analysed by flow cytometry. Error bars are the mean \pm SD of $n=2$ donors measured in duplo. ns, not significant, by two-tailed, unpaired Student's *t*-test. HCV, Hepatitis C virus; IDV, Indinavir; RAL, Raltegravir; UI, uninfected.




Figure 4. Mature and HIV-1-infected LCs retain infectious HCV for transmission.

(A) Epidermal sheets were exposed to HIV-1 (JRCSF) for 24 hours and subsequently exposed to pseudotyped HCV (HIV-1 NL4.3 Δ env pseudotyped with HCV env glycoproteins E1 and E2) for another 24 hours, extensively washed, co-cultured with huh7.5 cells and analysed for luciferase reporter activity. Horizontal bars are the means of $n=7$ donors measured triplo and quadruplo. ** $p < 0.01$, by two-tailed, paired Student's *t*-test. (B) Mature LCs were exposed to pseudotyped HCV (HIV-1 NL4.3 Δ env pseudotyped with HCV env glycoproteins E1 and E2) for 24 hours, extensively washed, co-cultured with huh7.5 cells and analysed for luciferase reporter activity. Horizontal bars are the means of $n=14$ donors measured in duplo, triplo and quadruplo. **** $p < 0.0001$, by two-tailed, paired Student's *t*-test. (C) Immature and mature LCs from the same donor were isolated, exposed to pseudotyped HCV (HIV-1 NL4.3 Δ env pseudotyped with HCV env glycoproteins E1 and E2) for 24 hours, extensively washed, co-cultured with huh7.5 cells and analysed for luciferase reporter activity. Error bars are the mean \pm SD of $n=3$ donors measured in triplicates. *** $p < 0.001$, by two-tailed, paired Student's *t*-test. HCV, Hepatitis C virus; iLC, immature Langerhans cell; mLC, mature Langerhans cell; UI, uninfected.

transmit HCV. To further compare the impact of maturation on LCs, we isolated immature and mature LCs from the same donor and performed a transmission assay. Mature but not immature LCs from the same donors efficiently transmitted HCV to Huh7.5 cells (Figure 4C). Furthermore, mature LCs efficiently bound HCV, which was rapidly internalized as trypsin treatment did not diminish HCV uptake (Figure S5). Thus, the maturation state alters the transmission capacity of LCs leading to virus retention for transmission. These findings

indicate that not only HIV-1 exposure, but also LC maturation by immune activation induces HCV transmission by LCs.

4 | DISCUSSION

The incidence of HCV is on the rise and re-infection rates are high in MSM living with HIV-1 [15,16]. Several studies suggest that HCV is transmitted via sexual contact within this

population [3–6,17,43]. Changes in sexual behaviour, immune activation by STIs, direct effects of HIV-1 infection or bleeding could be involved in the observed HCV susceptibility upon sexual contact [12,44–46]. Here, we identified an important role for mucosal LCs in allowing HCV entry into mucosal tissues, where the virus remains infectious for transmission by LCs to target cells. The retention of HCV in mucosal tissues by LCs might allow entry of virus into the blood or into lymphoid tissues where LCs might transfer the virus to other cells leading to dissemination to the liver.

Anal intercourse is the primary route for HIV-1 infection among MSM [47], underscoring the importance of the anal mucosa as entry site for sexually transmitted viruses. Interestingly, LCs are present in sigmoid colon and rectal mucosal tissue observed by immunohistochemistry [26]. Furthermore, it has been shown that LCs are present in HIV-1 negative MSM anal tissue [48–50]. We have identified and quantified LCs in anal mucosa of HIV-1 positive MSM biopsies. The presence of LCs within mucosal biopsies suggests that LCs are a potential target for HCV during sexual intercourse. Primary LCs were detected in anal mucosal biopsies at similar levels as observed in epidermis, suggesting that mucosal LCs similarly as in skin surveil for invaders. Moreover, mucosal LCs were similar to skin LCs as both subsets expressed high levels of the LC marker CD1a and langerin, whereas they lacked expression of DC-SIGN. Due to the very low numbers of LCs isolated from anal biopsies, we used primary skin LCs to investigate their role in HCV susceptibility after sexual contact. Throughout our study we used HCV concentrations that were similar to those found in semen of HIV-1 infected individuals [21,51,52]. Notably, neither immature nor mature LCs were infected by replication competent HCV. Moreover, activation of mature LCs by TLR ligands did not induce replication of HCV in LCs. Similarly, LCs were not infected by HCV in the *ex vivo* tissue model, and HIV-1 exposure did not lead to productive HCV infection of LCs *ex vivo*. These data strongly suggest that LCs do not become infected by HCV and therefore infection of LCs is not involved in mucosal HCV dissemination.

Although immature LCs were not able to transmit HCV to hepatocytes, HIV-1 exposure to LCs or maturation of LCs induced HCV transmission to hepatocytes. Hepatitis C virus transmission by HIV-1-exposed or mature LCs was independent of HCV infection as single-cycle pseudotyped HCV were transmitted by LCs after HIV-1 exposure. Thus, our data suggest that HIV-1 infection or activation alters the ability of LCs and allows retention of infectious HCV for transmission to target cells. Mature LCs were very efficient in uptake of HCV and further studies are required to identify the molecular mechanism. HIV-1 replication is important in HCV retention by LCs, as treating tissues *ex vivo* with different antiretroviral inhibitors abrogated the induced transmission of HCV to hepatocytes. As most MSM living with HIV-1 are under treatment with cART, these data suggest that either low level of HIV-1 replication in LCs or activation of LCs by HIV-1 or co-infections might result in enhanced HCV susceptibility. Moreover, our data strongly suggest that the maturation state of LCs is involved in HCV transmission as not only HIV-1 infection but also maturation of LCs enhanced HCV transmission.

It remains unclear whether there is ongoing replication of HIV-1 within immune cells in cART treated individuals. Some studies have observed low levels of HIV-1 replication in

lymphoid tissue biopsies from infected humans under cART, which was associated with lower antiretroviral drug concentrations in these tissues [53,54]. However, other studies were not able to detect HIV-1 replication in patients under cART [55–57]. Our data suggest that not only HIV-1 infection but also tissue activation enhances sexual transmission of HCV.

Immature LCs protect against HIV-1 infection by inducing langerin-mediated autophagic degradation of captured HIV-1 [58], whereas maturation of LCs allows infection and subsequent transmission of HIV-1 to T cells [23,41,59]. Similarly, our data suggest that immature LCs do not transmit HCV possibly via langerin but, strikingly, maturation of LCs changes this protective behaviour and allows transmission of HCV independent of replication. Thus, maturation of LCs might be important in allowing HCV entry into mucosal tissues.

Several receptors are able to facilitate this so-called trans-transmission of HCV to target cells, such as DC-SIGN and L-SIGN [24]. Interestingly neither immature nor mature LCs express DC-SIGN or L-SIGN, suggesting that another receptor might be involved. Heparan sulfates such as Syndecans are important in HCV infection of hepatocytes [60]. As these receptors are involved in trans-transmission of HIV-1 [61], it is possible that this family of receptors also facilitate trans-transmission of HCV by mature LCs. The ability to transmit HCV might also be associated with lower expression of langerin on mature LCs as langerin has anti-viral properties [40]. Further studies are required to identify the molecular mechanisms that are involved in HCV transmission by mature LCs.

Despite positive treatment outcome after the introduction of successful DAA, MSM are at high risk for HCV reinfection [15,16]. Several factors could account for the increased HCV susceptibility observed in MSM such as more porous rectal mucosa or cellular changes within rectal mucosa [12,62]. The ability by LCs to transmit HCV is not only triggered by HIV-1 as we also showed that mature LCs transmitted HCV. These data strongly suggest that other STIs as well as mucosal immune activation might enhance HCV susceptibility. Indeed, sexually-transmitted diseases are very prevalent within the MSM population such as HSV-2, Chlamydia, HPV infection, gonorrhoea and syphilis [44–46]. Our data strongly suggest that HIV-1 exposed or mature mucosal LCs efficiently capture and retain infectious HCV. The retention of HCV in mucosal tissues might increase the chance of HCV to enter the blood, or HCV might be transmitted by LCs to lymphocytes in mucosal tissues or after migration into the lymphoid tissues thereby allowing dissemination of HCV. Interestingly, HCV replication has been detected in peripheral blood mononuclear cells, suggesting that these cells might be involved in dissemination [63]. Here we have uncovered an important role for primary LCs present in anal mucosa in HCV susceptibility. Further investigation into the efficacy of cART in mucosal tissues might lead to better understanding of the role of HIV-1 in LC activation.

5 | CONCLUSIONS

Our data strongly indicate that HIV-1 or immune activation lead to capture and retention of HCV by mucosal LCs, which might facilitate transmission to other cells or entry into the blood. Novel therapies targeting HCV interaction with LCs

and abrogation of LC activation by HIV-1 or other STIs might prevent HCV transmission. This study will help further characterize the biological mechanisms underlying mucosal HCV transmission in MSM living with HIV-1.

AUTHORS' AFFILIATIONS

¹Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ²Department of Medical Microbiology, Clinical Virology Laboratory, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ³Department of Global Health, Amsterdam University Medical Centers, and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers HIV Monitoring Foundation, Amsterdam, The Netherlands; ⁴Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; ⁵Department of Dermatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

COMPETING INTEREST

All authors declare that they have no competing interests.

AUTHORS' CONTRIBUTIONS

B.M.N. performed and designed the research study, analysed the data and wrote the paper. R.S.F. performed and designed parts the research study. G.S.S. performed parts of the research study and analysed the data. R.R.C.E.S. performed parts of the research study and analysed the data. S.M.K. performed parts of the research. R.M. designed the research study. J.S. designed parts of the research study. P.R. designed parts of the research study. M.L.S.H. contributed essential material. M.V. contributed essential material and designed parts of the research study. C.M.S.R. designed parts of the research study. T.B.H.G. was involved in all aspects of the study.

ACKNOWLEDGEMENTS

We are grateful to the Boerhaave Medical Centre (Amsterdam, The Netherlands) and A. Knottenbelt (Flevo clinic Almere, The Netherlands) for the provision of human skin tissues.

FUNDING

This work was supported by Aidsfonds (P-11118), European Research Council, Advanced grant (670424) and The Netherlands Organization for Scientific Research NWO (VENI 863.13.025 and VIDI 91718331). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis*. 2016;16:797–808.
2. Wandeler G, Dufour JF, Bruggmann P, Rauch A. Hepatitis C: a changing epidemic. *Swiss Med Wkly*. 2015;145:1–9.
3. Wandeler G, Gsponer T, Bregenzler A, Günthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV cohort study: a rapidly evolving epidemic. *Clin Infect Dis*. 2012;55:1408–16.
4. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted Hepatitis C virus infection in HIV-positive men who have sex with men. *AIDS*. 2015;29:2335–45.
5. van de Laar TJW, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV Incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. *J Infect Dis*. 2007;196:230–8.
6. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. *Curr Opin HIV AIDS*. 2011;6:451–8.
7. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-Infected Individuals in the Australian trial in acute Hepatitis C. *Clin Infect Dis*. 2009;48:650–8.

8. Richardson D, Fisher M, Sabin CA. Sexual transmission of Hepatitis C in MSM May not be confined to those with HIV infection. *J Infect Dis*. 2008;197:1213–4.
9. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfecting with human immunodeficiency virus/Hepatitis C virus. *Hepatology*. 2009;50:1056–63.
10. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and Hepatitis C virus coinfecting patients. *Hepatology*. 1999;30:1054–8.
11. Thomas DL, Astemborski J, Vlahov D, Strathdee SA, Ray SC, Nelson KE, et al. Determinants of the quantity of Hepatitis C virus RNA. *J Infect Dis*. 2000;181:844–51.
12. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, et al. Trouble with bleeding: risk factors for acute Hepatitis C among HIV-positive gay men from Germany-A case-control study. *PLoS ONE*. 2011;6:28–32.
13. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. *Clin Infect Dis*. 2001;32:492–7.
14. Naggie S, Curtis C, Workowski K, Ruane P, Towner WJ, Marks K, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfecting with HIV-1. *N Engl J Med*. 2015;373:705–13.
15. Lambers FAE, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of Hepatitis C virus re-infection after treatment of sexually acquired acute Hepatitis C virus infection in HIV-infected MSM. *AIDS*. 2011;25:F21–7.
16. Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. *J Hepatol*. 2017;66:282–7.
17. van de Laar TJW, Matthews GV, Prins M, Danta M. Acute Hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *AIDS*. 2010;24:1799–812.
18. Marinovich B, Castilla J, del Romero J, García S, Hernando V, Raposo M, et al. Absence of Hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. *Sex Transm Infect*. 2003;79:160–2.
19. Braun DL, Marzel A, Steffens D, Schreiber PW, Grube C, Scherrer AU, et al. High rates of subsequent asymptomatic sexually transmitted infections and risky sexual behavior in patients initially presenting with primary human immunodeficiency virus-1 infection. *Clin Infect Dis*. 2018;66:735–42.
20. van Hommerig JW, Lambers FA, Schinkel J, Geskus RB, Arends JE, van der Laar TJ, et al. Risk factors for sexual transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men who have sex with Men: a case-control Study. *Open Forum Infect Dis*. 2015;2:1–8.
21. Foster AL, Gaisa MM, Hijdra RM, Turner SS, Morey TJ, Jacobson KB, et al. Shedding of Hepatitis C virus into the rectum of HIV-infected men who have sex with men. *Clin Infect Dis*. 2017;64:284–8.
22. Beyrer C, Baral SD, Van Griensven F, Goodreau SM, Chariyalertsak S, Wirtz AL, et al. Global epidemiology of HIV infection in men who have sex with men. *Lancet*. 2012;380:367–77.
23. De Jong MAWP, De Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TBH. TNF- α and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. *J Clin Invest*. 2008;118:3440–52.
24. Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by Hepatitis C virus. *PNAS*. 2004;101:14067–72.
25. Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious Hepatitis C virus pseudotype particles. *J Biol Chem*. 2004;279:32035–45.
26. Preza GC, Tanner K, Elliott J, Yang OO, Anton PA, Ochoa M-T. Antigen-presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 dendritic cells and CD209 macrophages. *AIDS Res Hum Retroviruses*. 2014;30:241–9.
27. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, et al. Sequence analysis of Hepatitis C virus isolated from a fulminant hepatitis patient. *J Med Virol*. 2001;64:334–9.
28. Connor R, Kuan Chen B, Choe S, Landau NR. VPR is required for efficient replication of Human Immunodeficiency virus Type-1 in Mononuclear Phagocytes. *Virology*. 1995. 206:935–44.
29. Kohn AD, Takeuchi F, Roth RA, Chem JB, Lemmon MA, Ferguson KM, et al. Transmission of Hepatitis C by intrahepatic inoculation with transcribed RNA. *Science*. 1997;277:5034.
30. Lindenbach BD, Evans MJ, Syder AJ, Tellinghuisen TL, Liu CC, Mckeating JA, et al. Complete replication of Hepatitis C virus in cell culture. *Science*. 2013;623:623–7.

31. de Jong MAWP, de Witte L, Santeogoets SJAM, Fluitsma D, Taylor ME, de Gruijl TD, et al. Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. *J Leukoc Biol.* **2010**;87:637–43.
32. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. *Science.* **1987**;236:819–22.
33. Cann AJ, Zack JA, Go AS, Arrigo SJ, Koyanagi Y, Green PL, et al. Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. *J Virol.* **1990**;64:4735–42.
34. Cheng-Mayer C, Levy JA. Distinct biological and serological properties of human immunodeficiency viruses from the brain. *Ann Neurol.* **1988**;23:S58–61.
35. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother.* **2002**;46:1896–905.
36. Liu S, Xiao L, Nelson C, Hagedorn C. A cell culture adapted HCV JFH1 Variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. *PLoS ONE.* **2012**;7:1–12.
37. Siegenbeek Van Heukelom ML, Marra E, De Vries HJC, Van Der Loeff MFS, Prins JM. Risk factors for anal high-grade squamous intraepithelial lesions in HIV-positive MSM: Is targeted screening possible? *AIDS.* **2017**;31:2295–301.
38. Hillman RJ, Cuming T, Darragh T, Nathan M, Berry-Lawthorn M, Goldstone S, et al. 2016 IANS international guidelines for practice standards in the detection of anal cancer precursors. *J Low Genit Tract Dis.* **2016**;20:283–91.
39. Schreurs RRCE, Drewniak A, Bakx R, Corpeleijn WE, Geijtenbeek THB, van Goudoever JB, et al. Quantitative comparison of human intestinal mononuclear leukocyte isolation techniques for flow cytometric analyses. *J Immunol Methods.* **2017**;445:45–52.
40. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. *Nat Med.* **2007**;13:367–71.
41. Sarrami-forooshani R, Mesman AW, Van Teijlingen NH, Sprockholt JK, Van der Vlist M, Ribeiro CMS, et al. Human immature Langerhans cells restrict CXCR4-using HIV-1 transmission. *Retrovirology.* **2014**;11:52.
42. Komurian-Pradel F, Perret M, Deiman B, Sodoyer M, Lotteau V, Paranhos-Baccalà G, et al. Strand specific quantitative real-time PCR to study replication of Hepatitis C virus genome. *J Virol Methods.* **2004**;116:103–6.
43. Kouyos RD, Rauch A, Böni J, Yerly S, Shah C, Aubert V, et al. Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol.* **2014**;43:887–96.
44. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. *Sex Transm Dis.* **2008**;35:946–59.
45. Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: san francisco, california, 2003. *Clin Infect Dis.* **2005**;41:67–74.
46. Li X, Li M, Yang Y, Zhong X, Feng B, Xin H, et al. Anal HPV/HIV co-infection among men who have sex with men: a cross-sectional survey from three cities in China. *Sci Rep.* **2016**;6:21368.
47. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. *Int J Epidemiol.* **2010**;39:1048–63.
48. Sobhani I, Walker F, Aparicio T, Abramowitz L, Henin D, Cremieux AC, et al. Effect of anal epidermoid cancer-related viruses on the dendritic (Langerhans) cells of the human anal mucosa. *Clin Cancer Res.* **2002**;8:2862–9.
49. Omine Y, Hinata N, Yamamoto M, Kasahara M, Matsunaga S, Murakami G, et al. Regional differences in the density of Langerhans cells, CD8-positive T lymphocytes and CD68-positive macrophages: a preliminary study using elderly donated cadavers. *Anat Cell Biol.* **2015**;48:177–87.
50. Sobhani I, Walker F, Roudot-Thoraval F, Abramowitz L, Johanet H, Henin D, et al. Anal carcinoma: incidence and effect of cumulative infections. *Aids.* **2004**;18:1561–9.
51. Bradshaw D, Lamoury F, Catlett B, Applegate TL, McAllister J, Dore GJ, et al. A comparison of seminal Hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals. *J Infect Dis.* **2015**;211:736–43.
52. Turner SS, Gianella S, Yip MJS, van Seggelen WO, Gillies RD, Foster AL, et al. Shedding of Hepatitis C virus in semen of human immunodeficiency virus-infected men. *Open Forum Infect Dis.* **2016**;3:1–6.
53. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. *Nature.* **2016**;530:51–6.
54. Fletcher CV, Staskus K, Wietgreffe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proc Natl Acad Sci.* **2014**;111:2307–12.
55. Strain M, Gunthard H, Havlir D, Ignacio C, Smith D, Leigh-Brown A, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. *Proc Natl Acad Sci.* **2003**;100:4819–24.
56. Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. *PLoS Pathog.* **2014**;10:e1004010.
57. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, Hirschel, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. *PNAS.* **2008**;105(43):16725–16730.
58. Ribeiro CMS, Sarrami-Forooshani R, Setiawan LC, Zijlstra-Willems EM, van Hamme JL, Tigchelaar W, et al. Receptor usage dictates HIV-1 restriction by human TRIM5 α in dendritic cell subsets. *Nature.* **2016**;540:448–52.
59. de Jong MA, de Witte L, Taylor ME, Geijtenbeek TBH. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. *J Immunol.* **2010**;185:1633–41.
60. Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of Hepatitis C virus to the surfaces of hepatocytes. *J Virol.* **2013**;87:6866–75.
61. Bobardt MD, Saphire ACS, Hung HC, Yu X, Van Der Schueren B, Zhang Z, et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. *Immunity.* **2003**;18:27–39.
62. Kaplan-Lewis E, Fierer DS. Acute HCV in HIV-Infected MSM: modes of acquisition, liver fibrosis, and treatment. *Curr HIV/AIDS Rep.* **2015**;12:317–25.
63. Pawełczyk A, Kubisa N, Jabłońska J, Bukowska-Ośko I, Caraballo Cortes K, Fic M, et al. Detection of Hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+. *Virol J.* **2013**;10:346.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Figure S1. Gating strategy of phenotyping LCs from anal biopsies.

Figure S2. DC-SIGN is not expressed by primary mucosal and skin LCs.

Figure S3. HIV-1 infection of mature LCs.

Figure S4. Mature Langerhans cells and MUTZ-LCs transmit HCV to hepatocytes.

Figure S5. Mature Langerhans cells bind and internalize HCV.